Cellectar Biosciences's market cap is currently ―. The company's EPS TTM is €; its P/E ratio is ―; Cellectar Biosciences is scheduled to report earnings on May 6, 2024, and the estimated EPS forecast is €-0.46. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 23	Jun 23	Mar 23	Dec 22	Sep 22
Income Statement	-
Total Revenue	-	-	-	-	$ 0.00
Gross Profit	-	-	-	-	-
EBIT	$ -7.51M	$ -8.22M	$ -8.58M	$ -7.42M	$ -7.82M
EBITDA	$ -7.44M	$ -8.18M	$ -8.54M	$ -7.38M	$ -7.78M
Net Income Common Stockholders	$ -7.45M	$ -8.22M	$ -8.58M	$ -7.22M	$ -7.81M
Balance Sheet	-
Cash, Cash Equivalents and Short-Term Investments	$ 9.56M	$ 5.15M	$ 12.68M	$ 19.87M	$ 17.79M
Total Assets	$ 12.08M	$ 6.51M	$ 14.84M	$ 21.59M	$ 19.32M
Total Debt	$ 552.98K	$ 584.50K	$ 599.45K	$ 603.83K	$ 201.97K
Net Debt	$ -9.01M	$ -4.57M	$ -12.08M	$ -19.26M	$ -17.58M
Total Liabilities	$ 13.43M	$ 6.98M	$ 7.50M	$ 6.08M	$ 6.57M
Stockholders Equity	$ -1.36M	$ -467.00K	$ 7.33M	$ 15.51M	$ 12.75M
Cash Flow	-
Free Cash Flow	$ -9.86M	$ -7.53M	$ -7.18M	$ -7.53M	$ -7.02M
Operating Cash Flow	$ -9.60M	$ -7.53M	$ -7.18M	$ -7.41M	$ -7.01M
Investing Cash Flow	$ -266.76K	-	-	$ -117.86K	$ -7.07K
Financing Cash Flow	$ 441.00K	-	$ 3.00	$ 9.61M	$ 0.00

Currency in USD

Cellectar Biosciences Earnings and Revenue History

Income Statement >

Cellectar Biosciences Debt to Assets

Balance Sheet >

Cellectar Biosciences Cash Flow

Cash Flow >

Cellectar Biosciences Forecast EPS vs Actual EPS

Earnings >

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing